Great news … i dont know will this ever reach Nepal or not … u are lucky @everhopeful …u guys get fastest availibilty of this med in ur country and europe… it has to pass 3rd phase as well… being hopeful bud…
@everhopeful @twinklestars do we actually know how min101 works? Does it target dopamine as do all aps? Or are they targeting a different circuitry?
I’ve no idea to be honest.
This is what Minerva says about it. It apparently modulates dopamine but not directly, it’s not a dopamine blocker.
“MIN-101 is meant to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking 5-HT2A promotes slow wave sleep, a sleep stage often disrupted in patients with schizophrenia.
Importantly, MIN-101 is also meant to block a specific subtype of sigma receptor called sigma2, which is involved in movement control, psychotic symptom control and learning and memory. Blocking sigma2 also modulates other neurotransmitters in the brain, in particular dopamine, which is important as individuals with schizophrenia often have elevated levels of dopamine in their brains. Blocking sigma2 also increases calcium levels in neurons in the brain, which can improve memory. Recent literature has also indicated that a sub-type of progesterone protein complex might also be a putative binding site for sigma2 receptors and might explain the effects on cognition of MIN-101.”
Guess I’ll have to wait for the first half of 2019 for the results. It seems like a long time to wait, but I like how they’re aiming for negative symptoms. I really hope this turns out to be a good drug.
I once had magic mushrooms (5ht2a agonist) and it did not make me psychotic, not at all. It made me feel alive. And from what i have read it makes ppl perceive life with more intensity. IMO it is the wrong target to try and cure sz.
Space cake now thats a different story.
5-HT2A is already a target of SGAs. It’s probably one of the important mechanisms of clozapine. They just haven’t figured out how to have this work without at least some D2 blocking. Plus of course clozapine hits a lot of other stuff too.
I don’t think any single neurotransmitters will offer a cure. Too complicated. Also too varied among individuals. But with more options, it’s more likely people will be able to find something that works for them. And maybe there will be personalized medicine in the future.
Anyone have a link to where the phase III locations are?
I don’t follow very closely the pipeline. There are some promising drugs in phase 1 and thereabouts though I think. But those will make it to nda in decades, not a good way to live life, closely following and hoping on something so far off.